Neurology Medical News about Temozolomide; pediatric low-grade glioma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Temozolomide in pediatric low-grade glioma
Pediatric Blood & Cancer, 07/26/07

Khaw, S.L., et al. - Temozolomide appears to be active in pediatric low-grade glioma, with the advantage of oral administration and excellent tolerability

Methods

Eligible patients had a diagnosis of low-grade glioma
Temozolomide was administered at a dose of 200 mg/m2 daily for 5 days, in a 4-week cycle
Therapy was stopped on completion of the targeted 12 cycles of chemotherapy or on evidence of tumor progression

Results

13 eligible patients were identified; 9 had a histological diagnosis of pilocytic astrocytoma;12 of them had received carboplatin prior to temozolomide, including 3 in combination with vincristine
111 cycles of therapy have been administered and hematological toxicity and nausea were the most common adverse effects
Median time to progression was 6.7 months (range 1.5-41.8 months)
EFSR at 3 years was 57%
12 of 13 patients remain alive at the time of report; 11 have stable disease

<< Previous
Specificity of frontal dysfunctions in relapsing–remitting...

Next >>
High-grade astrocytoma in very young children